QCM Cayman’s Abiomed Inc ABMD Stock Holding History

QCM Cayman’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-837	Closed	-$271K	–	334
2020 Q4	$271K	Buy	+837	New	+$232K	0.28%	134
2019 Q1	–	Sell	-881	Closed	-$286K	–	123
2018 Q4	$286K	Buy	+881	New	+$306K	1.17%	32

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

QCM Cayman's ABMD Position: Q1 2021 in Review

QCM Cayman sold out of Abiomed Inc (ABMD) in Q1 2021, closing a stake of 837 shares — an estimated $271K sold.

QCM Cayman first reported a position in ABMD in Q4 2018 and held it in 2 quarters. The position peaked at $286K in Q4 2018. 487 funds tracked by Wall St. Rank hold ABMD as of Q1 2021.

QCM Cayman reported no remaining Abiomed Inc position as of Q1 2021 after selling out during the quarter.
QCM Cayman sold 837 Abiomed Inc shares in Q1 2021, an estimated $271K.
QCM Cayman first reported a position in Abiomed Inc in Q4 2018 and held it in 2 quarters.
QCM Cayman's Abiomed Inc position peaked at $286K in Q4 2018.
487 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2021.

Based on QCM Cayman's 13F filing for Q1 2021, filed 17 May 2021.